Efficacy and Safety Study of Tesamorelin in Chronic Obstructive Pulmonary Disease (COPD) Subjects With Muscle Wasting

This study has been terminated.
(The study was terminated based on a non-safety related corporate decision.)
Information provided by (Responsible Party):
ClinicalTrials.gov Identifier:
First received: July 5, 2011
Last updated: April 4, 2014
Last verified: April 2014

A significant proportion of COPD subjects experience muscle wasting, which has been associated with increased morbidity, impaired physical functioning, and a poor quality of life.

Muscle wasting is associated with reduced muscle strength in COPD subjects. In particular, weakness of peripheral muscles has been reported to play an important role in the reduced functional capacity and impaired exercise performance.

The primary objective of this study is to investigate the effect of tesamorelin, in conjunction with exercise training, on lean body mass measured by dual energy x-ray absorptiometry (DXA) scan.

Condition Intervention Phase
Chronic Obstructive Pulmonary Disease (COPD)
Drug: Tesamorelin
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Two Doses of Tesamorelin in Stable Ambulatory COPD Subjects With Muscle Wasting

Resource links provided by NLM:

Further study details as provided by Theratechnologies:

Primary Outcome Measures:
  • Change From Baseline in Lean Body Mass at 6 Months [ Time Frame: 6 months ] [ Designated as safety issue: No ]
    The primary objective of the study was to evaluate the effect of tesamorelin on lean body mass by Dual-energy X-ray absorptiometry (DXA) scan

Secondary Outcome Measures:
  • Change From Baseline in Exercise Capacity at 6 Months [ Time Frame: 6 months ] [ Designated as safety issue: No ]
  • Change From Baseline in Peripheral Muscle Strength at 6 Months [ Time Frame: 6 months ] [ Designated as safety issue: No ]
  • Change From Baseline in Patient-reported Outcomes at 6 Months [ Time Frame: 6 months ] [ Designated as safety issue: No ]
  • Adverse Events [ Time Frame: 6 months ] [ Designated as safety issue: Yes ]
    Number and percentage of subjects with adverse events

  • COPD Exacerbations [ Time Frame: 6 months ] [ Designated as safety issue: Yes ]
    Frequency and severity of COPD exacerbations

  • Plasma Glucose [ Time Frame: 6 months ] [ Designated as safety issue: Yes ]
    Changes from baseline in fasting blood glucose

Enrollment: 3
Study Start Date: September 2011
Study Completion Date: December 2011
Primary Completion Date: December 2011 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Tesamorelin 2 mg
Tesamorelin 2 mg/day
Drug: Tesamorelin
Experimental: Tesamorelin 3 mg
Tesamorelin 3 mg/day
Drug: Tesamorelin
Placebo Comparator: Placebo


Ages Eligible for Study:   40 Years to 75 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Male or female subjects aged 40-75 years (y) inclusive
  • Documented diagnosis of moderate to very severe COPD (GOLD stage 2, 3, or 4)
  • Stable COPD (i.e., no exacerbation) for at least 6 weeks prior to screening
  • Able to participate in a supervised exercise training program
  • Evidence of muscle wasting

Exclusion Criteria

  • Participation in a pulmonary rehabilitation program or in any supervised exercise program during the 4 months prior to screening
  • More than 4 exacerbations in the year prior to screening
  • Life-threatening exacerbation in the year prior to screening
  • Requirement for long-term oxygen therapy (> 12 hours of oxygen per day)
  • Critical illness or co-morbid conditions that may interfere with study conduct or endpoint measurements
  • Use of agents known to increase lean body mass within 3 months prior to screening
  • Hypopituitarism, history of pituitary tumor/surgery, head irradiation, or severe head trauma
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01388920

Sponsors and Collaborators
Principal Investigator: Richard Casaburi, PhD, MD University of California, Los Angeles
  More Information

No publications provided

Responsible Party: Theratechnologies
ClinicalTrials.gov Identifier: NCT01388920     History of Changes
Other Study ID Numbers: TH9507-CTR-1025 
Study First Received: July 5, 2011
Results First Received: April 4, 2014
Last Updated: April 4, 2014
Health Authority: United States: Food and Drug Administration

Keywords provided by Theratechnologies:
Muscle wasting

Additional relevant MeSH terms:
Lung Diseases
Lung Diseases, Obstructive
Muscular Atrophy
Pulmonary Disease, Chronic Obstructive
Nervous System Diseases
Neurologic Manifestations
Neuromuscular Manifestations
Pathological Conditions, Anatomical
Respiratory Tract Diseases
Signs and Symptoms
Growth Hormone-Releasing Hormone
Hormones, Hormone Substitutes, and Hormone Antagonists
Pharmacologic Actions
Physiological Effects of Drugs

ClinicalTrials.gov processed this record on February 11, 2016